Skip to main content
    F

    Fennec Pharmaceuticals Inc (FENC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.76
    +1.14 (+9.81%)

    Market Cap: $410.25M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fennec Pharmaceuticals Inc (FENC) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Fennec Pharmaceuticals are Fulcrum Therapeutics (FULC), Nuvectis Pharma (NVCT) and Prothena Corporation (PRTA). By market cap, Fennec Pharmaceuticals ranks 7th of the 13 companies on this page; Nuvectis Pharma (NVCT) is the largest at $696.03M.

    Peer Comparison

    FENC's revenue growth of 57.3% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Fennec Pharmaceuticals (FENC)$410.25M159.5x6.8x3.0%N/A57.3%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Puma Biotechnology Inc (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    X4 Pharmaceuticals Inc (XFOR)$318.59MN/A21.7x0.0%-36.9%63.1%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Peer median$408.79M15.0x4.4x0.0%-32.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Fennec Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Puma Biotechnology Inc (PBYI)
    Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States...
    PBYI competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    X4 Pharmaceuticals Inc (XFOR)
    X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development...
    XFOR competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors

    Frequently Asked Questions About FENC

    Who are Fennec Pharmaceuticals' main competitors?

    The companies most similar to Fennec Pharmaceuticals include Fulcrum Therapeutics (FULC), Nuvectis Pharma (NVCT), Prothena Corporation (PRTA), Puma Biotechnology (PBYI) and Phathom Pharmaceuticals (PHAT), listed from the closest match.

    Who is Fennec Pharmaceuticals' biggest competitor?

    Nuvectis Pharma (NVCT) is the largest of the similar companies at $696.03M; Fulcrum Therapeutics (FULC) is the closest match by business profile, size, sector and industry.

    How does FENC stock compare with its competitors?

    FENC's P/E is 159.5x against a peer median of 15.0x; its P/S is 6.8x against a peer median of 4.4x; its net margin is 3.0% against a peer median of 0.0%.

    Which of Fennec Pharmaceuticals' competitors pays a higher dividend?

    Fennec Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Fennec Pharmaceuticals bigger than its competitors?

    No. Fennec Pharmaceuticals is 7th by market cap among the 13 companies on this page; the largest is Nuvectis Pharma (NVCT) at $696.03M.